Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5918_Библиотеки_им_академика_М_И_Перельмана
.pdf
126
https://t.me/med1917
S. Yadav et al.
7.9.2 Articial Intelligence inDrug Delivery Optimisation
The combination of AI and drug delivery has transformed this eld. AI algorithms
analyse large amounts of data, considering patient-specic variables, drug kinetics,
and dynamics. This data-driven method supports in the design of personalised drug
delivery regimens for specic patients, optimising dosage, timing, and formulation.
AI-powered platforms increase treatment outcomes and patient experiences, signalling a paradigm shift in the personalisation of DDSs.
7.9.3 Stimulus-Triggered Drug Release Systems
Stimulus-triggered drug release systems are an advanced technique to targeted drug
delivery. These systems are responsive to external stimuli like light, magnetic elds,
even ultrasound, allowing medicinal drugs to be released on demand. This level of
control improves drug delivery precision, allowing clinicians to strategically schedule and localise treatment, optimising therapeutic effects (Park 2016).
7.10 Future Developments andEmerging Technologies
The future of biotechnology is marked by transformative trends and emerging technologies. Advances in CRISPR technology promise precise genetic engineering,
while synthetic biology opens avenues for creating synthetic organisms. Articial
intelligence is revolutionising drug discovery, enabling personalised medicine based
on individual genetic proles. Advanced bioprocessing techniques and nanomedicine applications are enhancing bioproduction and targeted medical interventions.
Microbiome manipulation, 3D bioprinting, and environmental biotechnology solutions contribute to health and sustainability. Neurotechnology advancements hold
promise for addressing neurological disorders. Interdisciplinary collaborations drive
these innovations, shaping a dynamic landscape for the future of biotechnology.
7.10.1 Biodegradable Implants
Biodegradable implants are an advanced technique in medical technologies that are
designed to degrade naturally within the body over time. Biocompatible materials
are frequently used in these implants, which gradually degrade into harmless
byproducts by enzymatic or hydrolysis processes. This controlled breakdown works
in parallel with the recovery process, helping throughout critical stages of tissue
regeneration.
7 Drug Delivery inBiotechnology: Present andFuture
https://t.me/med1917
Traditional drug delivery routes such as oral, transdermal, rectal, parenteral,
and nasal techniques provide benets such as convenience of administration and
systemic effects. On the other hand, each route has its own set of challenges. Oral
administration encounters problems such as acidity in the gastric tract, hepatic
metabolism, and the growth of microbes that can cause absorption concerns,
especially in chronic conditions that require regular dosage (Liu et al. 2017).
Although parenteral methods provide excellent absorption, they are invasive and
can result in poor patient compliance (Vhora etal. 2021). Transdermal patches
can address some concerns; however, they encounter barriers such as the stratum
corneum. The requirement for several daily doses causes difculties for chronic
conditions (Jeong etal. 2021). Implants with regulated drug release avoid these
challenges by assuring sustained drug concentrations, providing a promising
alternative for improved treatment outcomes in a patient-friendly way (GarcíaEstrada etal. 2021).
Biodegradable implants have numerous applications in biotechnology. They are
employed in orthopaedics for bone xation, ultimately paving the way to regenerated tissues. Biodegradable polymers act as carriers in drug delivery, releasing therapeutic substances in a regulated manner. Biodegradable cardiovascular stents assist
blood arteries during healing and gradually disintegrate, reducing long-term consequences. These implants reduce the number of procedures required to eliminate
non-biodegradable devices, improving patient compliance. Implants provide superior safety, improved bioavailability, a controlled delivery rate, improved permeability, and minimal toxicity (Sharma etal. 2021). Examples of these biodegradable
implants include drug-eluting stents, tissue engineering scaffolds, pacemakers, cardiac valves, or ocular implants (Johnson etal. 2021).
Ritasert®, an FDA-approved ocular insert intended to treat chronic uveitis, incorporated polyvinyl alcohol as a polymer for sustaining drug delivery. This device can
provide drug delivery for up to 3years. Similarly, PMMA-based implants are frequently used in bone-related scaffolds for joint replacement procedures to enable
sustained drug delivery. Bioinspired cardiac valves were 3D printed after being created with silicone to serve as a polymeric agent. Under physiological heart conditions, the invitro data revealed good hemodynamic function of the heart valves.
These implants can be made of biodegradable or non-biodegradable polymers.
Implantable drug delivery devices have numerous applications, including disease
detection, treatment, regenerative therapies, and preventive therapies (Chavda
etal. 2022).
127
7.10.2 Articial Intelligence inDrug Delivery
Articial intelligence (AI) is transforming drug delivery by improving precision, efciency, and personalised treatment techniques. A major application is
predictive modelling, which employs machine learning algorithms (MLA) to
analyse large datasets to forecast drug behaviour, formulation consequences,
128
https://t.me/med1917
S. Yadav et al.
and patient responses. This helps to improve the design of focused drug delivery
systems. AI is especially important in personalised medicine, where it is used to
customise drug delivery techniques to specic patient proles by utilising
genetic, genomic, and clinical data. With AI-driven platforms discovering prospective candidates and optimising formulations, the future of AI in the administration of drugs holds promise for faster drug development. This game-changing
technology is expected to improve the precision and efcacy of DDSs, introducing a new era of personalised and effective therapies. Examples of AI used in
drug delivery are:
IBM Watson to support Drug Discovery: Uses AI to analyse various biomedical
data sources to identify drug candidates more efciently. When domain annotators
are applied to massive volumes of unstructured data using IBM Watson technology,
the processing speed extracts molecules, genes, and drugs from hundreds of thousands of scientic papers and patents in hours. Human collection of this information
would most likely take much longer. Annotators’ information gathered from hundreds of millions of pages of text can subsequently be assembled into a wide range
of runtime analytics including visualisations (Chen etal. 2016).
Atomwise: Uses AI to predict their afnity for binding of tiny compounds to
specic therapeutic targets, hence speeding up drug discovery. Atomwise serves as
an AI drug discovery startup that has created the AtomNet platform, which uses
deep learning algorithms for identifying potential drug candidates. They announced
the identication of many molecules with potential anti-disease activity in 2019,
such as Ebola, cystic brosis, and multiple sclerosis. Certain chemicals are now
being tested to see if they have the potential to be novel therapies for certain disorders (Anusha etal. 2023).
Benevolent AI: Uses AI to optimise therapeutic efcacy through drug discovery
and repurposing. Analyse scientic research sets of data, then generate unique
insights by forming and qualifying hypotheses (Narayanan etal. 2022).
Tempus (A Vast Data Library for Personalised Healthcare): Uses AI to analyse
clinical and genomic data to provide personalised cancer treatment plans, including drug delivery optimisation. To personalise healthcare treatments, Tempus
uses AI to lter through the world’s largest database of clinical and biological
data. The company is developing AI technologies that collect and analyse data in
areas that range from the sequencing of genes to image recognition, allowing
physicians to have a better understanding of treatments and cures. Tempus is
presently applying AI-powered data to cancer investigation and treatment
(Mohd 2022).
BERG Health: (Using AI to treat rare diseases): BERG acts as a clinical-stage,
AI-powered biotech platform that diagnoses diseases to rapidly accelerate up the
research and development of new treatments. BERG can develop stronger product
candidates for rare diseases by integrating its “Interrogative Biology” method with
standard R&D. BERG recently announced their research on the treatment of
Parkinson’s disease. They employed AI to discover previously discovered interactions among chemicals in the human body (Mohd 2022).
7 Drug Delivery inBiotechnology: Present andFuture
https://t.me/med1917
129
7.10.3 Exosome-Based Therapies
Exosome-based therapies are a novel approach to drug delivery in the eld of biotechnology. Exosomes, composed of microscopic extracellular vesicles released by
cells, are essential for intercellular communication. Their specic characteristics,
including stability, biocompatibility, and the capacity to cross biological barriers
(BBB), make them ideal drug delivery candidates. Exosomes are expected to revolutionise drug delivery in following ways in the future of biotechnology: They are
natural drug carriers that encapsulate therapeutic payloads such as proteins and
nucleic acids, providing a biocompatible framework for drug administration (El
Andaloussi etal. 2013). Engineered exosomes improve specicity and reduce offtarget effects, allowing for precise drug delivery. Their use extends to facilitating the
transport of nucleic acid medication to target cells, including RNA interference or
even gene editing tools, demonstrating versatility in biotechnological treatments
(Alvarez-Erviti etal. 2011). Exosomes, specically, can cross biological barriers,
such as the formidable BBB, thereby improving drug delivery to targeted organs.
Furthermore, by controlling the immune response, their immunomodulatory actions
lead to improved treatment results, increasing their prospective applications. As the
eld of drug delivery continues to develop, continuing research efforts are centred
on realising the maximum potential of exosomes over precise and personalised drug
administration, providing new solutions to conventional difculties (Pitt etal. 2017).
Exosomes high in MHC-II were produced by transfecting murine melanoma cells
with the CIITA gene, which resulted in an overexpression of MHC-II at their surfaces. This is an example of how designer exosomes are used immunotherapeutically.
The modied exosomes were then directed at T cells, where they improved the type
1 T-helper cells response against cancer cells. As a result, the modied exosomes’
enhanced MHC-II molecule served as both a targeting peptide and a therapeutic drug
(Lee etal. 2011). Alternatively, to drive exosomes towards T cells, an antibody with
a light chain can be added to the exosomal surface (Raposo and Stoorvogel 2013).
Curcumin-loaded exosomes have been investigated as potential means of drug delivery for Parkinson’s disease therapy. Haney etal. (2015) have demonstrated the usage
of naturally occurring anti-inammatory chemicals encapsulated within exosomes
(Kim etal. 2016; Haney etal. 2015). Researchers aimed to overcome multidrug resistance (MDR) in cancer cells by designing exosomes that contained doxorubicin,
demonstrating their utility as anticancer drug carriers (Kim etal. 2016).
7.10.4 Synthetic Biology Approaches
The use of modied microbes in drug delivery is a cutting-edge strategy with signicant future applications in the discipline of biotechnology. Synthetic biology
approaches allow microorganisms to be modied to serve as sophisticated carriers
for medicinal payloads. These genetically modied bacteria can be designed to
navigate complicated biological surroundings, target specic tissues, and even
130
https://t.me/med1917
release therapeutic chemicals in a controlled way. This novel approach has tremendous potential for facilitating the development of very precise and effective medication delivery systems. Biotechnology applications can include the targeted
administration of drugs, biological products, or gene treatments for a variety of
medical problems. Current advances in synthetic biology are projected to rene and
increase the potential of engineered microbes, changing the future panorama of
drug delivery across biotechnology (Callura etal. 2012).
The natural evolution of living organisms has resulted in the formation of increasingly sophisticated natural genetic networks for sensing the environment and
responding advantageously. As a result, many synthetic biologists anticipate using
this strategy to utilise the complexity of cells to create programmed therapeutic cells
that are capable of independently controlling and regulating both intrinsic (that are
located within cells) and extrinsic (located outside cells) signals to ght disease. To
achieve this goal, there are three signicant initiatives underway in the eld of synthetic biology, which involve engineering cells to:
Function as sensors, sensing and reporting the availability of specic molecules
that can differentiate among states of cells (i.e. healthy vs. diseased/damaged).
Perceive a specic molecule or cell state and responding by generating a controlled dosage of therapeutic biological molecules.
Function in different delivery platforms (Muldoon etal. 2021).
The key difference between synthetic biology and molecular biology is the fact
that synthetic biology assembles components from molecular biology (for example,
repressor proteins) to create innovative genetic frameworks that execute complex
activities. Dynamic gene expression, rewiring endogenous pathways to generate
biomolecules, controlling the number of cells, reporting on the condition of various
surroundings, and executing Boolean logic operations are among these functions
(MacDonald and Deans 2016).
Controlling gene expression reliably is critical in synthetic biology for developing functioning genetic circuits inside cells. These circuits can work independently
or in conjunction with existing biological networks. For independent functioning,
genetic circuits are frequently engineered to exist orthogonal to their host, to ensure
the regulatory control components are distinct from the host signalling pathways.
The integration of Boolean logic gates within these circuits enables exact control
over time, duration, and functionality, which is made possible by specic triggered
inputs. Various research techniques in molecular biology or genetic engineering act
as modular elements for synthetic biologists. These methods are critical for building
genomic circuits that allow sophisticated regulation of cell function, thereby advancing synthetic biology (MacDonald and Deans 2016).
S. Yadav et al.
7.10.5 3D Printing ofDDSs
3D printing advances are revolutionising DDSs by enabling the fabrication of personalised and extremely precise dose forms. This method enables healthcare formulations to be tailored to individual patient needs, considering parameters like age,
7 Drug Delivery inBiotechnology: Present andFuture
https://t.me/med1917
weight, and unique medical problems. Layer-by-layer application of pharmaceutical ingredients is used to construct complicated structures, allowing for unparalleled
management of the design and content of drug delivery systems. By optimising drug
release proles and boosting bioavailability, this customisation improves patient
compliance and overall therapeutic results. The adaptability of 3D printing for the
administration of medications demonstrates an evolutionary change towards personalised treatment, providing a promising path for medicines in the future (Chia
and Wu 2015).
3D printing enables the production of DD devices with varying geometries and/
or customised drug release characteristics, which are difcult to create using traditional drug manufacturing procedures. The DDS design, as well as the choice of
polymers and their combinations, can inuence drug release kinetics. Dosing in the
printed DDS can be changed to meet the demands of the patient by adjusting the
size of the printed formulations and changing the composition of the solid
material(s). The ability and versatility of the 3D printed DDS to independently tune
the drug delivery of numerous pharmaceuticals make it suited for patient groups
that require multiple drugs at the same time, such as individuals with metabolic illnesses. Designing formulations containing complicated inner structures and compartmentalised matrix systems could yield these DDS (Khaled etal. 2015).
Aprecia® Pharmaceuticals, which was created in 2003, was the rst pharmaceutical
business to introduce a 3D printed healthcare product. ZipDose® Technology was
developed in 2008 as a patented 3D printing process primarily for producing high-dose
and easy-to-swallow product for central nervous system therapies. GlaxoSmithKline
(GSK) and other pharmaceutical companies have showed interest in this subject as
well. Printing techniques have already been investigated for the generation of highthroughput screening matrices for drug screening and testing. Pharmaceutical and
printing rms are collaborating to create more affordable and personalised healthcare
solutions in the future. Furthermore, 3D printed human skin and organs provide a viable alternative to animal testing for cosmetic and biological research. Apart from 3D
printing technologies, 2D printing technologies such as inkjet as well as exographic
printing have also been used in the pharmaceutical industry. Flexography makes use of
rotary-type contact printing technology, whereas inkjet printers are non-contact systems based on ongoing or drop-on-demand jetting technologies (Palo etal. 2017).
131
7.11 Challenges andLimitations Associated withCurrent
Drug Delivery
7.11.1 Bioavailability
Bioavailability challenges involve addressing concerns such as low drug solubility
as well as degradation. Innovative formulations, such as nanoparticle-based systems
and prodrugs, are critical in enhancing drug absorption and systemic distribution,
ultimately increasing bioavailability.
132
https://t.me/med1917
S. Yadav et al.
7.11.2 Immunogenicity
Immunogenicity is a problem in biologic therapies because the immune response of
the body might affect the effectiveness of therapeutic agents. A signicant focus is
on strategic drug design, which includes adjustments to minimise immunogenicity.
This comprises structural changes as well as the application of immunomodulatory
drugs to extend biologics’ therapeutic lifetime.
7.11.3 Non-specic Distribution
Non-specic drug distribution can result in undesirable adverse effects. Off-target
effects are minimised using advanced drug delivery technologies like liposomes and
targeted formulations. However, improving these systems to facilitate accurate targeting along with controlled release is still a difculty in drug delivery studies.
Addressing these issues collectively is critical for improving DDSs and patient outcomes (Vizirianakis 2004).
7.11.4 Safety Concerns
The progress of DDSs in biotechnology creates new obstacles and ethical concerns.
As novel techniques, such as nanotechnology and precision delivery methods,
become fundamental to biopharmaceutical research, safety issues take centre stage.
These technologies’ complicated interactions with biological systems raise concerns about potential toxicity, its immunogenicity, and long-term impacts. As biotechnological DDSs affect cells and molecules, it is essential that their safety and
biocompatibility be ensured. Ethical considerations include issues such as informed
consent, which is especially important in the context of developing medicines such
as gene editing and personalised medicine. Establishing a balance between expanding boundaries of biotechnology while protecting patient well-being necessitates
thorough risk assessments, close monitoring, and constant ethical debate among the
biotechnological and healthcare communities (Orive etal. 2003).
7.12 Conclusion
Biotechnology’s dynamic eld of drug delivery has made great progress, bringing
cutting-edge approaches to healthcare concerns. Nanotechnology, liposomal nanotechnology, and TDD emerge out as powerful techniques that have the potential to
revolutionise therapeutic precision and efcacy. The adaptability of liposomal
7 Drug Delivery inBiotechnology: Present andFuture
https://t.me/med1917
133
nanotechnology extends to therapies for cancer, diagnostics, and cosmeceuticals,
whereas incorporated NPs improve absorption and permit controlled release. With
the emergence of AI, exosome-based medicines, and synthetic biology, the future
holds enormous promise. These breakthroughs herald a new era of personalised and
targeted interventions, with applications ranging from cancer therapy to genetics
circuit regulation. However, this changing landscape raises important problems and
ethical concerns, emphasising the importance of continual safety assessments and
shared ethical debate. In the future, continued research and development will be
essential for achieving all that is possible with these technologies. Addressing problems, improving safety protocols, as well as exploring new applications will drive
the next wave of biotechnological drug delivery achievements. Researchers, physicians, ethicists, and regulators shall collaborate to design a healthcare future in
which these technologies play a critical role in providing individualised and effective therapies for various healthcare-related diseases.
References
Abdella S, Abid F, Youssef SH, Kim S, Anjuomo F, Malinga C, Song Y, Garg S (2023) pH and its
applications in targeted drug delivery. Drug Discov Today 28:103414
Adler-Moore J, Proftt RT (2002) AmBisome: liposomal formulation, structure, mechanism of
action and pre-clinical experience. J Antimicrob Chemother 49:21–30. https://doi.org/10.1093/
jac/49.suppl_1.21
Adli M (2018) The CRISPR tool kit for genome editing and beyond. Nat Commun 9:1911
Alcaraz J, Cinquin P, Martin DK (2018) Tackling the concept of symbiotic implantable medical
devices with nanobiotechnologies. Biotechnol J 13:1800102
Al-Jamal W, Kostarelos K (2011) Liposomes: from a clinically established drug delivery system to
a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 44:1094–1104
Allami RH, Yousif MG (2023) Integrative AI-driven strategies for advancing precision medicine
in infectious diseases and beyond: a novel multidisciplinary approach. arXiv Prepr arXiv
2307:15228
Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of
dose. Biochim Biophys Acta 1068:133–141
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA (2011) Delivery of siRNA to the
mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345
Anusha K, Jasmitha KSM, Sattibabu K, Reddy G (2023) Integrating of articial intelligence in
drug discovery and development: a comparative study. Pharmacophore 14:35–40. https://doi.
org/10.51847/anvmzrz4x4
Aslam H, Shukrullah S, Naz MY, Fatima H, Hussain H, Ullah S, Assiri MA (2022) Current and
future perspectives of multifunctional magnetic nanoparticles based controlled drug delivery
systems. J Drug Deliv Sci Technol 67:102946
Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M,
Siepmann F, Siepmann J (2022) Clinical translation of advanced colonic drug delivery tech-
nologies. Adv Drug Deliv Rev 181:114076
Badwaik HR, Kumari L, Nakhate K, Verma VS, Sakure K (2019) Chapter 13—phytoconstituent
plumbagin: chemical, biotechnological and pharmaceutical aspects. In: Atta-ur-Rahman (ed)
Bioactive natural products. Elsevier, pp415–460
Balazs DA, Godbey WT (2011) Liposomes for use in gene delivery. J Drug Deliv 2011:1
134
https://t.me/med1917
Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next genera-
tion of antibody–drug conjugates. Nat Rev Drug Discov 16:315–337
Bhatia S (2016) Natural polymer drug delivery systems: nanoparticles, plants, and algae
Billmeier U, Dieterich W, Neurath MF, Atreya R (2016) Molecular mechanism of action of anti-
tumor necrosis factor antibodies in inammatory bowel diseases. World J Gastroenterol 22:9300
Birla S, Singh N, Shukla NK (2022) Nanotechnology: device design and applications. CRC Press
Boas U, Christensen JB, Heegaard PMH (2007) Dendrimers in medicine and biotechnology: new
molecular tools. Royal Society of Chemistry
Bovier PA (2008) Epaxal®: a virosomal vaccine to prevent hepatitis a infection. Expert Rev
Vaccines 7:1141–1150
Brahmer JR, Hammers H, Lipson EJ (2015) Nivolumab: targeting PD-1 to bolster antitumor
immunity. Future Oncol 11:1307–1326
Burrows R, Lambrix E (2022) mRNA vaccines: a growing and complex IP landscape. Vaccine
Insights 1:191–199
Bzowska M, Karabasz A, Szczepanowicz K (2018) Encapsulation of camptothecin into pegylated
polyelectrolyte nanocarriers. Colloids Surf A Physicochem Eng Asp 557:36–42
Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA (2017) Doxorubicin: nanotech-
nological overviews from bench to bedside. Drug Discov Today 22:270–281. https://doi.
org/10.1016/j.drudis.2016.11.005
Callura JM, Cantor CR, Collins JJ (2012) Genetic switchboard for synthetic biology applications.
Proc Natl Acad Sci 109:5850–5855
Cessak G, Kuzawińska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, Bałkowiec-Iskra E
(2014) TNF inhibitors–mechanisms of action, approved and off-label indications. Pharmacol
Rep 66:836–844
Chavda VP, Jogi G, Paiva-Santos AC, Kaushik A (2022) Biodegradable and removable implants
for controlled drug delivery and release application. Expert Opin Drug Deliv 19:1177–1181.
https://doi.org/10.1080/17425247.2022.2110065
Chen Y, Elenee Argentinis JD, Weber G (2016) IBM Watson: how cognitive computing can be
applied to big data challenges in life sciences research. Clin Ther 38:688–701. https://doi.
org/10.1016/j.clinthera.2015.12.001
Chia HN, Wu BM (2015) Recent advances in 3D printing of biomaterials. J Biol Eng 9:1–14
Chilkoti A, Dreher MR, Meyer DE, Raucher D (2002) Targeted drug delivery by thermally respon-
sive polymers. Adv Drug Deliv Rev 54:613–630
Chouhan D, Janani G, Chakraborty B, Nandi SK, Mandal BB (2018) Functionalized PVA–silk
blended nanobrous mats promote diabetic wound healing via regulation of extracellular
matrix and tissue remodelling. J Tissue Eng Regen Med 12:e1559–e1570
Chow D, Nunalee ML, Lim DW, Simnick AJ, Chilkoti A (2008) Peptide-based biopolymers in
biomedicine and biotechnology. Mater Sci Eng R Rep 62:125–155
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés
Á, Picardi M (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s
lymphoma. N Engl J Med 378:331–344
Corrigan PA, Cicci TA, Auten JJ, Lowe DK (2014) Ado-trastuzumab emtansine: a HER2-positive
targeted antibody-drug conjugate. Ann Pharmacother 48:1484–1493
Crommelin DJA, Mastrobattista E, Hawe A, Hoogendoorn KH, Jiskoot W (2020) Shifting para-
digms revisited: biotechnology and the pharmaceutical sciences. J Pharm Sci 109:30–43
Daglar B, Ozgur E, Corman ME, Uzun L, Demirel GB (2014) Polymeric nanocarriers for expected
nanomedicine: current challenges and future prospects. RSC Adv 4:48639–48659
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanopar-
ticles: an overview of biomedical applications. J Control Release 161:505–522
Dhanaraj SA, Muralidharan S, Kanniappan P, Hui WTS, Qi LL (2016) Formulation and evalua-
tion of chitosan nanospheres containing methotrexate targeted drug delivery system. J Young
Pharm 8:330
S. Yadav et al.
7 Drug Delivery inBiotechnology: Present andFuture
https://t.me/med1917
du Plessis HL, Marais EB, Mohammed F, Kotze AF (2014) Applications of lipid based formula-
tion technologies in the delivery of biotechnology-based therapeutics. Curr Pharm Biotechnol
15:659–672
El Andaloussi S, Mäger I, Breakeeld XO, Wood MJA (2013) Extracellular vesicles: biology and
emerging therapeutic opportunities. Nat Rev Drug Discov 12:347–357
Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B,
Eng G, Langer R (2005) Microuidic system for studying the interaction of nanoparticles and
microparticles with cells. Anal Chem 77:5453–5459
García-Estrada P, García-Bon MA, López-Naranjo EJ, Basaldúa-Pérez DN, Santos A, Navarro-
Partida J (2021) Polymeric implants for the treatment of intraocular eye diseases: trends in
biodegradable and non-biodegradable materials. Pharmaceutics 13:701
Giantonio BJ (2009) Goldie–Coldman and bevacizumab beyond disease progression. Nat Rev Clin
Oncol 6:311–312
(2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated
block copolymers. Proc Natl Acad Sci 105:2586–2591
Guenoun J, Koning GA, Doeswijk G, Bosman L, Wielopolski PA, Krestin GP, Bernsen MR (2012)
Cationic Gd-DTPA liposomes for highly efcient labeling of mesenchymal stem cells and cell
tracking with MRI.Cell Transplant 21:191–205
Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, Takahashi M, Jinnai
S, Shimoyama R, Sakai A (2020) Application of articial intelligence technology in oncology:
towards the establishment of precision medicine. Cancers (Basel) 12:3532
Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky
M, Kabanov AV (2015) Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J
Control Release 207:18–30
He W, Hosseinkhani H, Mohammadinejad R, Roveimiab Z, Hueng D, Ou K, Domb AJ (2014)
Polymeric nanoparticles for therapy and imaging. Polym Adv Technol 25:1216–1225
Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: advances in nanoparticle
technology for drug delivery in neuro-oncology. Int J Mol Sci 23:4153
Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo
M, Horhota A (2012) Preclinical development and clinical translation of a PSMA-targeted
docetaxel nanoparticle with a differentiated pharmacological prole. Sci Transl Med 4:128ra39
Iwata A, Sai S, Nitta Y, Chen M, de Fries-Hallstrand R, Dalesandro J, Thomas R, Allen MD (2001)
Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial
activation and leukocyte inltration in transplanted hearts. Circulation 103:2753–2759
Jeong WY, Kwon M, Choi HE, Kim KS (2021) Recent advances in transdermal drug delivery
systems: a review. Biomater Res 25:1–15
Jesorka A, Orwar O (2008) Liposomes: technologies and analytical applications. Annu Rev Anal
Chem 1:801–832
Johnson AR, Forster SP, White D, Terife G, Lowinger M, Teller RS, Barrett SE (2021) Drug elut-
ing implants in pharmaceutical development and clinical practice. Expert Opin Drug Deliv
18:577–593
Kaida-Yip F, Deshpande K, Saran T, Vyas D (2018) Biosimilars: review of current applications,
obstacles, and their future in medicine. World J Clin Cases 6:161
Kamaly N, Yameen B, Wu J, Farokhzad OC (2016) Degradable controlled-release polymers and
polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 116:2602–2663.
https://doi.org/10.1021/acs.chemrev.5b00346
Kesharwani P, Jain K, Jain NK (2014) Dendrimer as nanocarrier for drug delivery. Prog Polym
Sci 39:268–307
Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ (2015) 3D printing of ve-in-one dose
combination polypill with dened immediate and sustained release proles. J Control Release
217:308–314
135
Соседние файлы в папке Библиотека им академика М.И. Перельмана